Nuclear medicine and biology · 2026
H3RESCA chelator-enabled [18F]AlF labeling: An optimized temperature-resilient platform for PSMA-targeted PET tracers in prostate cancer.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yukai, Hu Zhoumi, Zhang Qingyu, Zhang Bowu, Li Jingye, Liu Jianjun, Wang Cheng
Аннотация
OBJECTIVE: Prostate-specific membrane antigen (PSMA) has emerged as a pivotal biomarker for the molecular imaging and targeted therapy of prostate cancer. To address the ongoing need for PSMA-targeting radiotracers with improved mild-labeling capability and reduced non-target organ exposure, beyond currently approved agents (e.g., [68Ga]Ga-PSMA-11) that require higher temperatures or show hepatobiliary clearance, a novel 18F-labeled PSMA inhibitor, [18F]AlF-H3RESCA-PSMA, was developed for PET imaging of prostate cancer.
METHODS: H3RESCA-PSMA was synthesized with an acyclic pentadentate chelator and radiolabeled with [18F]AlF at room temperature. Biodistribution and PET/CT studies were performed in PSMA-positive tumor xenografts, with [18F]AlF-PSMA-RESCA1 as comparator.
RESULTS: Radiochemical yield was 75.5 ± 5.0%. [18F]AlF-H3RESCA-PSMA showed 2-fold higher tumor uptake and slower wash-out versus PSMA-RESCA1, while exhibiting markedly reduced liver and kidney retention. PET images revealed superior tumor contrast and faster background clearance.
CONCLUSIONS: [18F]AlF-H3RESCA-PSMA offers enhanced PSMA-targeting specificity and imaging contrast, supporting its clinical translation for prostate cancer PET.
METHODS: H3RESCA-PSMA was synthesized with an acyclic pentadentate chelator and radiolabeled with [18F]AlF at room temperature. Biodistribution and PET/CT studies were performed in PSMA-positive tumor xenografts, with [18F]AlF-PSMA-RESCA1 as comparator.
RESULTS: Radiochemical yield was 75.5 ± 5.0%. [18F]AlF-H3RESCA-PSMA showed 2-fold higher tumor uptake and slower wash-out versus PSMA-RESCA1, while exhibiting markedly reduced liver and kidney retention. PET images revealed superior tumor contrast and faster background clearance.
CONCLUSIONS: [18F]AlF-H3RESCA-PSMA offers enhanced PSMA-targeting specificity and imaging contrast, supporting its clinical translation for prostate cancer PET.